Business Wire

ALTER-DOMUS

25.11.2021 08:02:10 CET | Business Wire | Press release

Share
Alter Domus Strengthens its Competitive Differentiation with Continued Investments in European Operational Excellence

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, is enhancing its European service offering by making substantial investments in its central operations.

The initiative is focused on building additional technology capability, expanding its European footprint, and continuing to recruit exceptional, multilingual talent to support Alter Domus in providing corporate and fund services to investors and managers in private equity, real assets, and debt capital markets.

Launching an Ambitious Digital Agenda

At the core of its €50 million investment is technology. Alter Domus is pursuing an ambitious digital agenda in software development, network and infrastructure, security and systems engineering, and quality assurance.

This complements the rollout of new client-facing technology, CorPro , digitalising investors’ and managers’ traditional workflows to significantly improve access to data and achieve efficiencies across different geographies, funds, and product types.

This in-house technology was enhanced with the acquisition of London-based SaaS platform, Credit-Vision, whose solution for corporate credit investors was vertically integrated into Alter Domus’ technology stack during 2021.

Scaling via European footprint

In addition to expanding its Irish operations in 2021, Alter Domus opened its doors in Lithuania and now benefits from operations centres in Cork, Vilnius, and Malta to house central operations as well as functions including technology and HR. In Ireland and Lithuania alone, Alter Domus has hired more than 200 new employees in 2021. Luxembourg continues to play a critical role in knowledge sharing to Alter Domus’ new operations centres as it remains a leading European centre of excellence.

Exceptional, Specialised Talent

Across Europe, Alter Domus plans to hire an additional 270 technology, accounting, legal, compliance and tax specialists in Luxembourg, Cork, and Vilnius in 2022, to scale across the continent.

This will support Alter Domus in capturing the growing demand for incremental outsourcing as global alternatives investment managers in North America and Asia – who have an estimated $2.5 trillioni in dry powder to deploy – increasingly look to Europe to launch and manage new funds.

Alter Domus has fully deployed a hybrid working model and benefited from a greater appetite amongst exceptional talent to switch functional roles since the beginning of the pandemic. Those alternatives specialists seeking to switch are demanding a more technology-centric role without losing their sector expertise.

Through a proprietary training program, The acADemy , Alter Domus employees are enhancing their technical, professional and leadership skills. 1,800 Alter Domus employees in 13 European locations have already benefited from The acADemy, amounting to over 30,000 hours of training delivery.

Sandra Legrand, Regional Executive for Europe at Alter Domus, said: “In a year when Alter Domus has topped $1 trillion in assets under administration, we have in place the strongest technological capabilities and expanded our talented central operations team to support our clients and the rising complexity of their assets.”

“Our technology investment programme is strengthening our ability to help alternatives investors and managers grapple with a data deluge. Our technology is optimising managers fund and portfolio performance when they’re raising, managing, and deploying funds, and reporting this all back to their end-investors to overcome the intricate web of regulatory and compliance requirements.”

Heather Crowley- Kerr, Head of Central Operations Europe at Alter Domus, said: “Fund administration is a people industry increasingly defined by digital transformation. Whilst we’re automating our processes to serve our clients more efficiently, we’ve more than doubled our workforce in central operations since 2016 to maintain our hybrid operating model which blends human with digital.”

“Through an internal knowledge transfer system, we’ve exported some deep technical knowledge and experience that sits within Luxembourg and Malta to two additional hubs in Cork and Vilnius which now employ over 350 people. In the last year, we’re proud to have trained over 175 employees in the entire alternatives product lifecycle, so we retain our competitive advantage in being the only fund services and asset administration provider solely dedicated to providing superior expertise to private equity, credit, real estate and infrastructure investors and managers.

We look forward to our continued growth within our central operations and to welcoming additional talent to join us on the Alter Domus journey.”

# #

ABOUT ALTER DOMUS

Alter Domus is a leading provider of fund administration, debt capital markets and corporate services for the alternative investment industry. Through vertical integration, dedicated teams provide support and bespoke solutions across entire value chains. By tapping into a talent pool of more than 3,300 employees across 36 offices in 21 jurisdictions, our expertise and cutting-edge technology combine to put clients ahead of the game.

With an established professional focus on private equity, venture capital, real estate, infrastructure, and credit sectors, we offer fund administration, debt capital markets services, corporate services, depositary services, capital administration, transfer pricing, domiciliation and management company services. Our specific experience in the debt capital markets sector allows us to provide specialist solutions such as loan administration, agency services, trade settlement and CLO manager services.

Alter Domus proudly serves 16 of the 20 largest private equity houses, 17 of the 20 largest real estate firms, and 17 of the 20 largest private debt managers in the world. For more information, please visit: www.alterDomus.com .


i Source: Preqin (as at November 2021) North America = $1.778 Tn and APAC = $0.762 Tn of dry powder

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye